Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis.

ABSTRACT:

SUBMITTER: Epperla N 

PROVIDER: S-EPMC10835265 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature